Structural basis of second-generation HIV integrase inhibitor action and viral resistance

Author:

Cook Nicola J.1ORCID,Li Wen23ORCID,Berta Dénes4ORCID,Badaoui Magd4ORCID,Ballandras-Colas Allison1ORCID,Nans Andrea5ORCID,Kotecha Abhay67ORCID,Rosta Edina4ORCID,Engelman Alan N.23ORCID,Cherepanov Peter18ORCID

Affiliation:

1. Chromatin Structure and Mobile DNA Laboratory, Francis Crick Institute, London NW1 1AT, UK.

2. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

3. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.

4. Department of Chemistry, King’s College London, London SE1 1DB, UK.

5. Structural Biology Science Technology Platform, Francis Crick Institute, London NW1 1AT, UK.

6. The Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.

7. Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, 5651 GG, Netherlands.

8. Department of Infectious Disease, Imperial College London, St Mary’s Campus, London W2 1PG, UK.

Abstract

Strengths and weaknesses of an HIV drug Retroviruses replicate by inserting a copy of their RNA, which has been reverse transcribed into DNA, into the host genome. This process involves the intasome, a nucleoprotein complex comprising copies of the viral integrase bound at the ends of the viral DNA. HIV integrase strand-transfer inhibitors (INSTIs) stop HIV from replicating by blocking the viral integrase and are widely used in HIV treatment. Cook et al. describe structures of second-generation inhibitors bound to the simian immunodeficiency virus (SIV) intasome and to an intasome with integrase mutations known to cause drug resistance. Passos et al. describe the structures of the HIV intasome bound to a second-generation inhibitor and to developmental compounds that are promising drug leads. These structures show how mutations can cause subtle changes in the active site that affect drug binding, show the basis for the higher activity of later-generation inhibitors, and may guide development of better drugs. Science , this issue p. 806 , p. 810

Funder

National Institutes of Health

Francis Crick Institute

Medical Research Council

Engineering and Physical Sciences Research Council

European Research Council

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3